Shares of IDEAYA Biosciences, Inc. (IDYA) are rising more than 17% Monday morning at $10.89, after the company announced positive interim results from the Phase 2 study of darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma (MUM) patients.
The company reported interim data from the study including tumor shrinkage in 89% of Any-Line MUM patients, as well as 50% of Overall Response Rate (ORR) in First-Line MUM.
IDYA has traded in the range of $8.14-$27.71 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.